Stocks & Investing
Wed, June 5, 2024
[ Wed, Jun 05th 2024
] - WOPRAI
Thu, February 29, 2024
[ Thu, Feb 29th 2024
] - WOPRAI
Mon, November 20, 2023
[ Mon, Nov 20th 2023
] - WOPRAI
Fri, August 4, 2023
[ Fri, Aug 04th 2023
] - WOPRAI
Thu, December 15, 2022
[ Thu, Dec 15th 2022
] - WOPRAI
[ Thu, Dec 15th 2022
] - WOPRAI
Tue, May 24, 2022
[ Tue, May 24th 2022
] - WOPRAI
Wed, April 27, 2022
[ Wed, Apr 27th 2022
] - WOPRAI
Andrea Tan Initiated (ARWR) at Hold and Held Target at $31 on, Jun 5th, 2024
Andrea Tan of Goldman Sachs, Initiated "Arrowhead Pharmaceuticals, Inc." (ARWR) at Hold and Held Target at $31 on, Jun 5th, 2024.
Andrea has made no other calls on ARWR in the last 4 months.
There are 5 other peers that have a rating on ARWR. Out of the 5 peers that are also analyzing ARWR, 2 agree with Andrea's Rating of Hold. Following are those relevant analyst calls for the last 4 months
- Michael Ulz of "Morgan Stanley" Maintained at Hold with Decreased Target to $27 on, Monday, May 13th, 2024
- Shawn Egan of "Citigroup" Maintained at Hold with Increased Target to $34 on, Wednesday, February 7th, 2024
These are the ratings of the 3 analyists that currently disagree with Andrea
- Keay Nakae of "Chardan Capital" Maintained at Strong Buy and Held Target at $60 on, Monday, June 3rd, 2024
- Patrick Trucchio of "HC Wainwright & Co." Reiterated at Strong Buy and Held Target at $90 on, Monday, June 3rd, 2024
- Luca Issi of "RBC Capital" Reiterated at Buy and Held Target at $50 on, Wednesday, February 7th, 2024
